Noema Pharma is a clinical-stage biotech company developing disease-modifying therapeutics for central nervous system conditions, including persistent seizures, severe pain, and involuntary tics. Their therapies aim to improve the quality of life for patients with both rare and common neurological disorders by targeting the underlying symptoms rather than merely managing them.
Funding
$209.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFounders
Product
Problem
Many central nervous system (CNS) disorders lack effective treatments that address the underlying causes of the condition, instead focusing on managing symptoms. This can lead to a reduced quality of life for patients with both rare and common neurological disorders. Current therapeutic options may not adequately improve the lives of individuals suffering from conditions such as persistent seizures, severe pain, and involuntary tics.
Solution
Noema Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapeutics for various CNS conditions. Their pipeline includes mid-clinical-stage therapeutics designed to target the underlying mechanisms of CNS-mediated diseases, aiming to provide more effective and long-lasting relief. The company's approach seeks to go beyond symptom control by developing treatments that can transform the lives of patients with conditions such as persistent seizures in tuberous sclerosis complex, severe pain in trigeminal neuralgia, and involuntary tics associated with Tourette Syndrome. Noema Pharma is also investigating treatments for Childhood Onset Fluency Disorder, VMS, and additional symptoms of menopause.
Target Audience
The primary target audience includes individuals suffering from CNS-mediated diseases such as persistent seizures, severe pain, and involuntary tics, as well as the healthcare professionals who treat them.
Features
- Developing therapeutics that target the underlying causes of CNS disorders.
- Pipeline includes mid-clinical-stage therapeutics for persistent seizures, severe pain, and involuntary tics.
- Investigating treatments for both rare and common neurological conditions.